Abstract
We investigated the changes in antibody titers after intravenous immunoglobulin (IVIg) administration in patients with neuromuscular diseases. Among patients who received IVIg from April 1, 2020, to August 31, 2022, we retrospectively evaluated 15 patients with antibody measurements before and after IVIg administration for any rise in the following antibody levels and examined the data for subsequent changes of false positive results to negative ones. The levels of anti SS-A, anti-thyroglobulin, anti-thyroid peroxidase, anti-glutamic acid decarboxylase, HBs, and HBc antibodies transiently increased after IVIg administration and showed false-positive results. However, levels of rheumatoid factor and anti-nuclear and antineutrophil cytoplasmic antibodies were not elevated. The false-positive results became negative after 3 months. Here, we report on the changes in antibody levels before and after IVIg administration and note that levels of hepatitis B virus-related antibodies and various autoantibodies transiently rise after IVIg administration.
| Translated title of the contribution | Altered antibody titers in patients with neuromuscular diseases after high-dose intravenous immunoglobulin therapy |
|---|---|
| Original language | Japanese |
| Pages (from-to) | 157-162 |
| Number of pages | 6 |
| Journal | Clinical Neurology |
| Volume | 64 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2024 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Clinical Neurology
Fingerprint
Dive into the research topics of 'Altered antibody titers in patients with neuromuscular diseases after high-dose intravenous immunoglobulin therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver